"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
(Generic versions may still be available.)
The sulfonamides should not be used for the treatment of group A beta-hemolytic streptococcal infections. In an established infection, they will not eradicate the streptococcus, and therefore will not prevent sequelae such as rheumatic fever and glomerulonephritis.
The presence of clinical signs such as sore throat, fever, arthralgia, cough, shortness of breath, pallor, purpura or jaundice may be early indications of serious reactions, including serious blood disorders.
Sulfonamides should be given with caution to patients with impaired renal or hepatic function and to those with severe allergy or bronchial asthma. In glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. This reaction is frequently dose-related.
Information for Patients
See PATIENT INFORMATION section.
Complete blood counts should be done frequently in patients receiving sulfonamides. If a significant reduction in the count of any formed blood element is noted, Gantanol (sulfamethoxazole) should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with impaired renal function.
See DRUG INTERACTIONS section.
Carcinogenesis: Sulfamethoxazole has not been adequately tested in animals to permit an evaluation of its carcinogenic potential.
Mutagenesis: Bacterial mutagenic studies have not been performed with sulfamethoxazole. No chromosomal damage was observed in human leukocytes cultured in vitro with sulfamethoxazole; the concentrations used exceeded blood levels of sulfamethoxazole following therapy with Gantanol (sulfamethoxazole) .
Impairment of Fertility: No adverse effects on fertility or general reproductive performance were observed in rats given sulfamethoxazole in oral dosages as high as 350 mg/kg/day.
Pregnancy Category C: In rats, oral doses of 533 mg/kg of sulfamethoxazole produced teratologic effects manifested mainly as cleft palates. The highest dose which did not cause cleft palates in rats was 512 mg/kg of sulfamethoxazole. In rabbits, 150 to 350 mg/kg/day increased maternal mortality but had no deleterious effects on fetal development.
There are no adequate and well-controlled studies of Gantanol (sulfamethoxazole) in pregnant women. Gantanol (sulfamethoxazole) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Gantanol (sulfamethoxazole) is not recommended in pediatric patients under 2 months of age, except in the treatment of congenital toxoplasmosis as adjunctive therapy with pyrimethamine (see CONTRAINDICATIONS). At the present time there are insufficient clinical data on prolonged or recurrent therapy in chronic renal diseases of pediatric patients under 6 years of age.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Gantanol Information
- Gantanol Drug Interactions Center: sulfamethoxazole oral
- Gantanol Side Effects Center
- Gantanol FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.